CA3239386A1 - Increasing drug bioavailability in naltrexone therapy - Google Patents

Increasing drug bioavailability in naltrexone therapy

Info

Publication number
CA3239386A1
CA3239386A1 CA3239386A CA3239386A CA3239386A1 CA 3239386 A1 CA3239386 A1 CA 3239386A1 CA 3239386 A CA3239386 A CA 3239386A CA 3239386 A CA3239386 A CA 3239386A CA 3239386 A1 CA3239386 A1 CA 3239386A1
Authority
CA
Canada
Prior art keywords
acceptable salt
pharmaceutically acceptable
naltrexone
bupropion
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3239386A
Other languages
English (en)
French (fr)
Inventor
Shawn Flanagan
Eduardo Dunayevich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nalpropion Pharmaceuticals LLC
Original Assignee
Nalpropion Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3239386(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nalpropion Pharmaceuticals LLC filed Critical Nalpropion Pharmaceuticals LLC
Publication of CA3239386A1 publication Critical patent/CA3239386A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3239386A 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy Pending CA3239386A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03
US61/419,395 2010-12-03
CA2819262A CA2819262C (en) 2010-12-03 2011-12-02 Pharmaceutical composition comprising naltrexone and buopropion for administration with food

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2819262A Division CA2819262C (en) 2010-12-03 2011-12-02 Pharmaceutical composition comprising naltrexone and buopropion for administration with food

Publications (1)

Publication Number Publication Date
CA3239386A1 true CA3239386A1 (en) 2012-06-07

Family

ID=46172304

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3239386A Pending CA3239386A1 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy
CA2819262A Active CA2819262C (en) 2010-12-03 2011-12-02 Pharmaceutical composition comprising naltrexone and buopropion for administration with food

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2819262A Active CA2819262C (en) 2010-12-03 2011-12-02 Pharmaceutical composition comprising naltrexone and buopropion for administration with food

Country Status (27)

Country Link
US (1) US20130245056A1 (enExample)
EP (5) EP2646031B9 (enExample)
JP (5) JP6008866B2 (enExample)
KR (5) KR20140035320A (enExample)
CN (1) CN103313711A (enExample)
AR (2) AR093182A1 (enExample)
AU (2) AU2011336304B2 (enExample)
BR (1) BR112013013390A2 (enExample)
CA (2) CA3239386A1 (enExample)
CL (1) CL2013001564A1 (enExample)
CY (2) CY1118968T1 (enExample)
DK (4) DK4349369T3 (enExample)
ES (3) ES2866879T3 (enExample)
FI (2) FI3884947T3 (enExample)
HR (4) HRP20170734T1 (enExample)
HU (3) HUE065852T2 (enExample)
IL (3) IL226504B (enExample)
LT (4) LT2646031T (enExample)
MX (2) MX384662B (enExample)
PL (4) PL3222280T3 (enExample)
PT (4) PT3884947T (enExample)
RS (4) RS65198B1 (enExample)
RU (1) RU2640561C2 (enExample)
SI (4) SI3884947T1 (enExample)
SM (4) SMT202100227T1 (enExample)
TW (1) TWI618536B (enExample)
WO (1) WO2012075459A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
PL3222280T3 (pl) * 2010-12-03 2021-11-29 Nalpropion Pharmaceuticals Llc Wzrost biodostępności leku w terapii naltreksonem
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
WO2016125109A1 (en) * 2015-02-07 2016-08-11 Intas Pharmaceuticals Ltd. Pharmaceutical composition for the treatment of obesity
EP3600433B1 (en) * 2017-03-28 2021-05-05 LDN Pharma Limited An agent that increases the expresssion of the bcl2-associated agonist of cell death for the treatment of cancer
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
US12303604B1 (en) * 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2007016108A1 (en) 2005-07-27 2007-02-08 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20070179168A1 (en) 2005-11-28 2007-08-02 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR101486228B1 (ko) * 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
KR101264789B1 (ko) * 2006-06-30 2013-05-15 엘지디스플레이 주식회사 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
WO2008011150A1 (en) * 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
SI3461503T1 (sl) * 2007-04-11 2022-04-29 Biomarin Pharmaceutical Inc. Postopki za dajanje tetrahidrobiopterina, povezani sestavki in postopki merjenja
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
PL3222280T3 (pl) 2010-12-03 2021-11-29 Nalpropion Pharmaceuticals Llc Wzrost biodostępności leku w terapii naltreksonem

Also Published As

Publication number Publication date
JP2019056004A (ja) 2019-04-11
TW201304780A (zh) 2013-02-01
FI4349369T3 (fi) 2025-12-17
SMT201700232T1 (it) 2017-07-18
IL279626A (en) 2021-03-01
KR101984500B1 (ko) 2019-05-31
EP3884947A1 (en) 2021-09-29
FI3884947T3 (fi) 2024-01-30
JP2024071605A (ja) 2024-05-24
US20130245056A1 (en) 2013-09-19
EP4349369B1 (en) 2025-09-17
DK4349369T3 (da) 2025-12-22
RU2013127423A (ru) 2015-01-10
ES3056642T3 (en) 2026-02-23
ES2625527T9 (es) 2018-09-25
HRP20251576T1 (hr) 2026-01-30
DK3222280T3 (da) 2021-04-19
AU2011336304B2 (en) 2017-03-30
EP2646031B9 (en) 2018-01-10
PL3222280T3 (pl) 2021-11-29
JP2022060331A (ja) 2022-04-14
ES2625527T3 (es) 2017-07-19
KR20140035320A (ko) 2014-03-21
KR102105857B1 (ko) 2020-05-04
HUE053831T2 (hu) 2021-07-28
KR20180069089A (ko) 2018-06-22
MX384662B (es) 2025-03-14
KR20200044158A (ko) 2020-04-28
IL226504B (en) 2021-01-31
HUE034393T2 (en) 2018-02-28
EP3222280A1 (en) 2017-09-27
AR124500A2 (es) 2023-04-05
IL270841A (en) 2020-01-30
JP6008866B2 (ja) 2016-10-19
HRP20170734T1 (hr) 2017-08-11
CY1124331T1 (el) 2022-07-22
CY1118968T1 (el) 2018-01-10
PT2646031T (pt) 2017-05-25
KR102258043B1 (ko) 2021-05-28
KR102391511B1 (ko) 2022-04-26
DK2646031T3 (en) 2017-05-22
RU2640561C2 (ru) 2018-01-09
HRP20210618T1 (hr) 2021-09-17
AU2011336304A1 (en) 2013-07-11
LT3884947T (lt) 2024-03-12
BR112013013390A2 (pt) 2016-09-06
CA2819262A1 (en) 2012-06-07
JP6456890B2 (ja) 2019-01-23
KR20190058702A (ko) 2019-05-29
EP3884947B1 (en) 2023-11-15
EP4349369A2 (en) 2024-04-10
AU2017204309A1 (en) 2017-07-13
PL3884947T3 (pl) 2024-05-06
SI3222280T1 (sl) 2021-11-30
EP4696322A2 (en) 2026-02-18
CN103313711A (zh) 2013-09-18
EP4696322A3 (en) 2026-04-15
PL4349369T3 (pl) 2026-03-23
EP3222280B1 (en) 2021-01-20
RU2017144631A3 (enExample) 2021-04-13
TWI618536B (zh) 2018-03-21
AR093182A1 (es) 2015-05-27
CA2819262C (en) 2024-05-28
HRP20240115T1 (hr) 2024-06-07
JP7025319B2 (ja) 2022-02-24
MX356801B (es) 2018-06-13
RS67527B1 (sr) 2026-01-30
EP2646031A4 (en) 2014-04-23
PL2646031T3 (pl) 2017-08-31
RS56014B1 (sr) 2017-09-29
PT3222280T (pt) 2021-04-22
SMT202500474T1 (it) 2026-01-12
MX2013006071A (es) 2013-10-01
RS65198B1 (sr) 2024-03-29
SI3884947T1 (sl) 2024-06-28
RU2017144631A (ru) 2019-02-18
PT4349369T (pt) 2025-12-17
SMT202400038T1 (it) 2024-03-13
SMT202100227T1 (it) 2021-07-12
LT3222280T (lt) 2021-05-10
EP4349369A3 (en) 2024-05-15
SI2646031T1 (sl) 2017-07-31
WO2012075459A1 (en) 2012-06-07
KR20210063473A (ko) 2021-06-01
LT2646031T (lt) 2017-06-26
JP2016210809A (ja) 2016-12-15
DK3884947T3 (da) 2024-01-22
EP2646031B1 (en) 2017-02-22
HUE065852T2 (hu) 2024-06-28
EP2646031A1 (en) 2013-10-09
LT4349369T (lt) 2026-01-12
SI4349369T1 (sl) 2026-02-27
JP2013544290A (ja) 2013-12-12
RS62149B1 (sr) 2021-08-31
PT3884947T (pt) 2024-02-16
ES2866879T3 (es) 2021-10-20
CL2013001564A1 (es) 2014-05-02

Similar Documents

Publication Publication Date Title
EP4349369B1 (en) Increasing drug bioavailability in naltrexone therapy
US20220233520A1 (en) Increasing Drug Bioavailability In Naltrexone Therapy
RU2781141C2 (ru) Повышение биодоступности лекарственных средств при терапии налтрексоном
HK1188136A (en) Increasing drug bioavailability in naltrexone therapy

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240821

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241118

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241122

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241126

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20241126

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250319

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251107

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251107